| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (NCT05269355) | PTC Therapeutics | 2022-05-23 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma (NCT05116800) | Brown University | 2022-03-01 |
| ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (NCT05116683) | Benjamin Izar | 2022-01-11 |
| Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (NCT05080790) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2021-11-15 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas (NCT04906876) | Brown University | 2021-09-01 |
| Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma (NCT05204524) | Chinese Academy of Medical Sciences | 2021-08-27 |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (NCT04554914) | Pierre Fabre Medicament | 2021-07-14 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma (NCT04996004) | Pfizer | 2021-06-22 |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients (NCT04811196) | University Health Network, Toronto | 2021-03-29 |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (NCT04031677) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-01-20 |
| A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma (NCT04624178) | Memorial Sloan Kettering Cancer Center | 2020-11-05 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (NCT04420975) | Jonsson Comprehensive Cancer Center | 2020-10-14 |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (NCT04055220) | Centre Leon Berard | 2020-03-03 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (NCT04242238) | Memorial Sloan Kettering Cancer Center | 2020-01-22 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778) | National Cancer Institute (NCI) | 2019-12-31 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas (NCT04214457) | Igenomix | 2019-09-20 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (NCT03899805) | Dana-Farber Cancer Institute | 2019-06-04 |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma (NCT03437070) | University of Miami | 2019-06-01 |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (NCT03851614) | University Health Network, Toronto | 2019-04-08 |
| A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) (NCT03761095) | PTC Therapeutics | 2019-03-13 |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin (NCT03773510) | Italian Sarcoma Group | 2019-02-28 |
| M6620 (VX-970) in Selected Solid Tumors (NCT03718091) | Massachusetts General Hospital | 2019-01-08 |
| Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (NCT03420014) | Philogen S.p.A. | 2018-12-27 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (NCT03526679) | National Taiwan University Hospital | 2018-07-12 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas (NCT03989596) | Maria Sklodowska-Curie National Research Institute of Oncology | 2018-06-01 |
| Vorinostat (SAHA) in Uterine Sarcoma (NCT03509207) | Medical University of Graz | 2017-12-14 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (NCT03016819) | Advenchen Laboratories, LLC | 2017-08-15 |
| A Study of Nivolumab in Selected Uterine Cancer Patients (NCT03241745) | Memorial Sloan Kettering Cancer Center | 2017-08-03 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall (NCT03651375) | Maria Sklodowska-Curie National Research Institute of Oncology | 2017-02-11 |
| Patient Reported Outcome Measures (PROMs) With Trabectedin (NCT03959033) | University of Leeds | 2016-11-29 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (NCT02584309) | Washington University School of Medicine | 2016-02-22 |
| Detection of Circulating Tumor Cells in Patients With Sarcomas (NCT02983539) | AC Camargo Cancer Center | 2015-10-01 |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (NCT02275286) | Grupo Espanol de Investigacion en Sarcomas | 2014-11-01 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (NCT02180867) | National Cancer Institute (NCI) | 2014-08-12 |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma (NCT02247544) | Italian Sarcoma Group | 2014-03-01 |
| Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (NCT01956084) | Catherine Bollard | 2013-11-01 |
| Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases (NCT01447056) | Baylor College of Medicine | 2012-02-01 |
| Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas (NCT01426633) | Heidelberg University | 2011-11-01 |
| Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine (NCT01442662) | UNICANCER | 2011-09-01 |
| Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (NCT01418001) | Memorial Sloan Kettering Cancer Center | 2011-08-01 |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (NCT01793168) | Sanford Health | 2010-07-01 |
| Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma (NCT02249702) | Mario Negri Institute for Pharmacological Research | 2010-04-01 |
| Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes (NCT00887809) | Memorial Sloan Kettering Cancer Center | 2009-04-01 |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma (NCT00837148) | Memorial Sloan Kettering Cancer Center | 2009-02-01 |
| Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (NCT00856050) | Dana-Farber Cancer Institute | 2009-02-01 |
| A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma (NCT00668148) | Eli Lilly and Company | 2008-07-01 |
| Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors (NCT00815945) | AGO Study Group | 2008-06-01 |
| Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung (NCT00503295) | Oncolytics Biotech | 2007-06-01 |
| Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (NCT00414076) | M.D. Anderson Cancer Center | 2006-12-19 |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma (NCT00400569) | H. Lee Moffitt Cancer Center and Research Institute | 2006-11-01 |
| Bevacizumab and Radiation Therapy for Sarcomas (NCT00356031) | Massachusetts General Hospital | 2006-07-01 |
| Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma (NCT00282087) | Sarcoma Alliance for Research through Collaboration | 2006-01-01 |
| Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (NCT00093080) | Merck Sharp & Dohme LLC | 2004-10-01 |
| LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (NCT00062868) | Baylor College of Medicine | 2003-09-01 |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer (NCT00060944) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-05-01 |